Figure 3 | Oncogenesis

Figure 3

From: Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma

Figure 3

Increased Sp1-binding to the CYP17A1 promoter in TMZ-resistant glioma cells. (a) Cells were subjected to CHIP assays, and the indicated promoter fragment was amplified by PCR. (b) The CYP17A1 promoter sequence contains two putative Sp1-binding sites. (c) Sp1-binding activity was determined by DAPA. After incubation of protein lysates with the biotinylated Sp1-binding sequence (S1 or S2 probe) and streptavidin beads, the beads were analyzed by western blotting with an anti-Sp1 antibody. (d) Quantitative results for Sp1 expression and Sp1-binding activity. Data are expressed as the means±s.e.m. (*P<0.05, **P<0.01, ***P<0.001). CHIP, chromatin immunoprecipitation; DAPA, DNA affinity precipitation assay.

Back to article page